AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, has announced $18 million in Australian Federal Government Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’.
With the support from the Medical Research Future Fund (MRFF) Frontiers Initiative, the goal of the multidisciplinary multi-institutional investigator team is to transform the clinical management of prostate cancer by leveraging leading therapeutic radiopharmaceutical technology paired innovative clinical development and a deep understanding of tumour biology to improve the lives of patients with prostate cancer.
The research programme is enabled by Australian startup AdvanCell’s proprietary (Lead-212) 212Pb alpha isotope production technology along with the delivery of a first-in-field clinical platform trial to accelerate the translation of 212Pb-based targeted alpha therapies, one of the most exciting breakthroughs in cancer treatment.
AdvanCell is collaborating with world-leading experts in Australia and globally, underpinning the transformative nature of the important clinical research.
